 Linda Barbour
Concepts (323)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 30 | 2023 | 282 | 9.090 |
Why?
| | Pregnancy Complications | 13 | 2021 | 430 | 2.980 |
Why?
| | Obesity | 20 | 2023 | 2517 | 2.470 |
Why?
| | Pregnancy | 63 | 2024 | 5548 | 2.390 |
Why?
| | Insulin Resistance | 15 | 2023 | 1078 | 2.210 |
Why?
| | Glyburide | 5 | 2018 | 35 | 2.090 |
Why?
| | Adiposity | 11 | 2023 | 468 | 2.050 |
Why?
| | Fetal Development | 6 | 2018 | 247 | 1.820 |
Why?
| | Blood Glucose | 15 | 2023 | 1824 | 1.670 |
Why?
| | Metformin | 4 | 2018 | 278 | 1.620 |
Why?
| | Pregnancy Outcome | 11 | 2022 | 336 | 1.500 |
Why?
| | Fetal Macrosomia | 4 | 2019 | 58 | 1.370 |
Why?
| | Infant, Newborn | 29 | 2023 | 5077 | 1.350 |
Why?
| | Diet, Fat-Restricted | 3 | 2023 | 73 | 1.170 |
Why?
| | Hypoglycemic Agents | 8 | 2018 | 1008 | 1.160 |
Why?
| | Diet, Diabetic | 3 | 2015 | 33 | 1.080 |
Why?
| | Birth Weight | 12 | 2021 | 438 | 1.040 |
Why?
| | Body Composition | 7 | 2017 | 580 | 0.900 |
Why?
| | Female | 67 | 2024 | 59913 | 0.850 |
Why?
| | Thyroid Crisis | 1 | 2022 | 7 | 0.840 |
Why?
| | Lipids | 2 | 2018 | 588 | 0.830 |
Why?
| | Placenta | 5 | 2022 | 624 | 0.820 |
Why?
| | Triglycerides | 4 | 2018 | 473 | 0.790 |
Why?
| | Insulin | 15 | 2022 | 2082 | 0.770 |
Why?
| | Abortion, Spontaneous | 2 | 2021 | 92 | 0.760 |
Why?
| | Pregnancy in Diabetics | 3 | 2021 | 82 | 0.730 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2004 | 64 | 0.730 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 159 | 0.710 |
Why?
| | Maternal Nutritional Physiological Phenomena | 6 | 2020 | 141 | 0.660 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2021 | 141 | 0.630 |
Why?
| | Nutrition Therapy | 1 | 2018 | 31 | 0.600 |
Why?
| | Humans | 71 | 2024 | 115587 | 0.600 |
Why?
| | Lipoprotein Lipase | 1 | 2018 | 55 | 0.600 |
Why?
| | Postprandial Period | 2 | 2018 | 88 | 0.590 |
Why?
| | Milk, Human | 5 | 2021 | 128 | 0.590 |
Why?
| | Premature Birth | 1 | 2021 | 278 | 0.580 |
Why?
| | Growth Hormone | 4 | 2007 | 99 | 0.570 |
Why?
| | Thromboembolism | 4 | 2001 | 93 | 0.570 |
Why?
| | Plethysmography | 3 | 2016 | 103 | 0.560 |
Why?
| | Muscle, Skeletal | 5 | 2014 | 1447 | 0.550 |
Why?
| | Insulin Receptor Substrate Proteins | 4 | 2011 | 56 | 0.510 |
Why?
| | Lipid Metabolism | 1 | 2018 | 449 | 0.510 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2020 | 447 | 0.510 |
Why?
| | Mothers | 8 | 2018 | 666 | 0.510 |
Why?
| | Absorptiometry, Photon | 2 | 2015 | 221 | 0.510 |
Why?
| | Hyperglycemia | 2 | 2019 | 294 | 0.500 |
Why?
| | Fatty Acids, Nonesterified | 6 | 2019 | 151 | 0.490 |
Why?
| | Maternal-Child Health Centers | 1 | 2014 | 9 | 0.480 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2007 | 332 | 0.480 |
Why?
| | Pregnancy Proteins | 3 | 2021 | 36 | 0.480 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 906 | 0.470 |
Why?
| | Adipose Tissue | 5 | 2018 | 555 | 0.470 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2021 | 2098 | 0.470 |
Why?
| | Practice Guidelines as Topic | 3 | 2018 | 1405 | 0.450 |
Why?
| | Dietary Fiber | 1 | 2013 | 40 | 0.450 |
Why?
| | Dietary Carbohydrates | 1 | 2014 | 135 | 0.440 |
Why?
| | Adult | 28 | 2024 | 30718 | 0.430 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 1724 | 0.410 |
Why?
| | Heparin | 5 | 2001 | 227 | 0.400 |
Why?
| | Monitoring, Ambulatory | 1 | 2012 | 82 | 0.400 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2014 | 500 | 0.400 |
Why?
| | Breast Feeding | 4 | 2020 | 370 | 0.390 |
Why?
| | Glucose | 4 | 2023 | 904 | 0.390 |
Why?
| | Glucose Tolerance Test | 6 | 2021 | 344 | 0.380 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2011 | 36 | 0.370 |
Why?
| | Anticoagulants | 5 | 2004 | 549 | 0.370 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 482 | 0.360 |
Why?
| | Fatty Liver | 1 | 2012 | 217 | 0.360 |
Why?
| | Glucose Intolerance | 1 | 2011 | 137 | 0.340 |
Why?
| | Infant | 9 | 2024 | 7979 | 0.340 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2014 | 794 | 0.330 |
Why?
| | Inflammation | 2 | 2018 | 2499 | 0.320 |
Why?
| | Fasting | 4 | 2019 | 241 | 0.310 |
Why?
| | Postpartum Period | 7 | 2020 | 281 | 0.310 |
Why?
| | Muscle Proteins | 2 | 2014 | 209 | 0.310 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 503 | 0.300 |
Why?
| | Obstetrics | 2 | 2018 | 161 | 0.300 |
Why?
| | Gestational Age | 3 | 2020 | 757 | 0.290 |
Why?
| | Pregnancy Complications, Hematologic | 2 | 2017 | 16 | 0.280 |
Why?
| | Prospective Studies | 8 | 2019 | 6264 | 0.270 |
Why?
| | Societies, Medical | 2 | 2018 | 684 | 0.260 |
Why?
| | Placental Hormones | 2 | 2003 | 4 | 0.260 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 3 | 2017 | 57 | 0.260 |
Why?
| | Venous Thrombosis | 2 | 2004 | 145 | 0.250 |
Why?
| | Lactation | 3 | 2021 | 149 | 0.250 |
Why?
| | Glycemic Index | 2 | 2015 | 21 | 0.240 |
Why?
| | Dalteparin | 1 | 2004 | 9 | 0.240 |
Why?
| | C-Peptide | 1 | 2023 | 138 | 0.210 |
Why?
| | Random Allocation | 1 | 2023 | 337 | 0.210 |
Why?
| | Microbiota | 2 | 2022 | 652 | 0.200 |
Why?
| | Patient Compliance | 3 | 2015 | 524 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 1 | 2012 | 3069 | 0.190 |
Why?
| | Emergencies | 1 | 2022 | 147 | 0.190 |
Why?
| | Life Style | 1 | 2024 | 429 | 0.190 |
Why?
| | Societies, Nursing | 1 | 2001 | 20 | 0.190 |
Why?
| | Pediatric Obesity | 2 | 2020 | 492 | 0.190 |
Why?
| | United States | 6 | 2022 | 12295 | 0.190 |
Why?
| | Interinstitutional Relations | 1 | 2001 | 55 | 0.190 |
Why?
| | Labor, Obstetric | 1 | 2001 | 53 | 0.190 |
Why?
| | Risk Factors | 6 | 2018 | 8697 | 0.190 |
Why?
| | Nurse Midwives | 1 | 2001 | 29 | 0.190 |
Why?
| | Male | 16 | 2021 | 55949 | 0.180 |
Why?
| | Hyperinsulinism | 1 | 2021 | 103 | 0.180 |
Why?
| | Mammary Glands, Human | 1 | 2020 | 60 | 0.180 |
Why?
| | Infant Formula | 1 | 2020 | 74 | 0.170 |
Why?
| | Body Mass Index | 6 | 2020 | 1971 | 0.170 |
Why?
| | Risk | 1 | 2022 | 819 | 0.170 |
Why?
| | Pregnancy Trimester, First | 2 | 2018 | 127 | 0.170 |
Why?
| | Delivery, Obstetric | 2 | 2017 | 119 | 0.170 |
Why?
| | Sleep Apnea Syndromes | 1 | 2020 | 74 | 0.170 |
Why?
| | Safety | 1 | 2001 | 298 | 0.170 |
Why?
| | Weight Loss | 1 | 2024 | 633 | 0.170 |
Why?
| | Signal Transduction | 3 | 2011 | 4541 | 0.170 |
Why?
| | Awards and Prizes | 1 | 2019 | 56 | 0.160 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3254 | 0.160 |
Why?
| | Anesthesia, Obstetrical | 1 | 2017 | 6 | 0.150 |
Why?
| | Body Weight | 3 | 2015 | 867 | 0.150 |
Why?
| | Analgesia, Obstetrical | 1 | 2017 | 17 | 0.150 |
Why?
| | Niacin | 1 | 2017 | 19 | 0.150 |
Why?
| | Heparin, Low-Molecular-Weight | 3 | 2004 | 29 | 0.150 |
Why?
| | Anemia, Aplastic | 1 | 2017 | 30 | 0.140 |
Why?
| | Glucose Transporter Type 1 | 1 | 2017 | 42 | 0.140 |
Why?
| | Carrier Proteins | 1 | 2021 | 701 | 0.140 |
Why?
| | Reference Values | 3 | 2007 | 744 | 0.140 |
Why?
| | Diet | 4 | 2022 | 1072 | 0.140 |
Why?
| | Protein S | 1 | 1996 | 6 | 0.140 |
Why?
| | Protein S Deficiency | 1 | 1996 | 6 | 0.140 |
Why?
| | Computational Biology | 1 | 2020 | 536 | 0.140 |
Why?
| | Thrombolytic Therapy | 1 | 1997 | 118 | 0.140 |
Why?
| | Complement Inactivator Proteins | 1 | 1996 | 40 | 0.140 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2016 | 46 | 0.140 |
Why?
| | Adipogenesis | 1 | 2016 | 42 | 0.130 |
Why?
| | Fetal Weight | 1 | 2016 | 52 | 0.130 |
Why?
| | Heart Valve Diseases | 1 | 1997 | 116 | 0.130 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2019 | 194 | 0.130 |
Why?
| | Niacinamide | 1 | 2016 | 65 | 0.130 |
Why?
| | Phosphorylation | 3 | 2014 | 1571 | 0.130 |
Why?
| | Umbilical Cord | 1 | 2016 | 80 | 0.130 |
Why?
| | Diet, High-Fat | 1 | 2017 | 225 | 0.130 |
Why?
| | Mice, Transgenic | 4 | 2007 | 1970 | 0.130 |
Why?
| | Metabolic Syndrome | 1 | 2019 | 324 | 0.130 |
Why?
| | Thrombophilia | 2 | 2009 | 66 | 0.130 |
Why?
| | Trophoblasts | 1 | 2017 | 162 | 0.130 |
Why?
| | Pandemics | 1 | 2024 | 1334 | 0.130 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2016 | 124 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2018 | 246 | 0.130 |
Why?
| | Young Adult | 4 | 2018 | 10470 | 0.120 |
Why?
| | Placenta Growth Factor | 2 | 2005 | 23 | 0.120 |
Why?
| | Anthropometry | 1 | 2015 | 181 | 0.120 |
Why?
| | Ultrasonography, Prenatal | 1 | 2016 | 235 | 0.120 |
Why?
| | Leptin | 1 | 2016 | 211 | 0.120 |
Why?
| | Antigens | 1 | 1996 | 323 | 0.120 |
Why?
| | Glycoproteins | 1 | 1996 | 309 | 0.120 |
Why?
| | Phosphoproteins | 3 | 2007 | 304 | 0.120 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2014 | 28 | 0.120 |
Why?
| | Fetus | 1 | 2018 | 702 | 0.120 |
Why?
| | Dietary Sucrose | 1 | 2013 | 45 | 0.110 |
Why?
| | Maternal-Fetal Exchange | 1 | 2014 | 151 | 0.110 |
Why?
| | Caloric Restriction | 1 | 2014 | 90 | 0.110 |
Why?
| | Patient Care Planning | 1 | 1994 | 142 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2018 | 3022 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1805 | 0.110 |
Why?
| | Fructose | 1 | 2013 | 100 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1216 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2018 | 686 | 0.110 |
Why?
| | Calcium Signaling | 1 | 2014 | 211 | 0.110 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 219 | 0.100 |
Why?
| | Biomedical Research | 1 | 2018 | 588 | 0.100 |
Why?
| | Thyroid Diseases | 1 | 2012 | 30 | 0.100 |
Why?
| | Thrombocytopenia | 1 | 1994 | 175 | 0.100 |
Why?
| | Cross-Over Studies | 1 | 2014 | 434 | 0.100 |
Why?
| | Prognosis | 2 | 2018 | 3339 | 0.100 |
Why?
| | Puerperal Disorders | 1 | 2012 | 31 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2353 | 0.100 |
Why?
| | Hyperthyroidism | 2 | 2012 | 26 | 0.100 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2005 | 281 | 0.100 |
Why?
| | Weight Gain | 3 | 2021 | 453 | 0.100 |
Why?
| | Health Promotion | 1 | 2018 | 693 | 0.100 |
Why?
| | Overweight | 1 | 2015 | 469 | 0.100 |
Why?
| | Software | 1 | 2015 | 541 | 0.090 |
Why?
| | Prenatal Care | 3 | 2019 | 257 | 0.090 |
Why?
| | Osteoporosis | 1 | 1994 | 227 | 0.090 |
Why?
| | Thrombosis | 1 | 1994 | 302 | 0.090 |
Why?
| | Pilot Projects | 1 | 2015 | 1377 | 0.090 |
Why?
| | Serine | 1 | 2011 | 125 | 0.090 |
Why?
| | Bone Density | 1 | 1994 | 432 | 0.090 |
Why?
| | Tyrosine | 1 | 2011 | 219 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2014 | 9159 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2013 | 458 | 0.090 |
Why?
| | BRCA2 Protein | 1 | 2009 | 42 | 0.080 |
Why?
| | Motor Activity | 1 | 2014 | 633 | 0.080 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 50 | 0.080 |
Why?
| | Warfarin | 2 | 2001 | 136 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 930 | 0.080 |
Why?
| | Prevalence | 1 | 2014 | 2264 | 0.080 |
Why?
| | Blotting, Western | 1 | 2011 | 1153 | 0.080 |
Why?
| | Pulmonary Embolism | 2 | 2001 | 182 | 0.070 |
Why?
| | Mice | 5 | 2018 | 15052 | 0.070 |
Why?
| | Fatty Acids, Volatile | 2 | 2018 | 47 | 0.070 |
Why?
| | Cohort Studies | 4 | 2019 | 4944 | 0.070 |
Why?
| | Hypothyroidism | 1 | 2007 | 65 | 0.070 |
Why?
| | Diet Surveys | 2 | 2017 | 78 | 0.070 |
Why?
| | Hormones | 1 | 2007 | 132 | 0.070 |
Why?
| | Time Factors | 2 | 2012 | 6165 | 0.070 |
Why?
| | Partial Thromboplastin Time | 2 | 1996 | 51 | 0.070 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 526 | 0.070 |
Why?
| | Adolescent | 4 | 2018 | 17889 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2004 | 1870 | 0.070 |
Why?
| | Adipocytes | 1 | 2007 | 188 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2012 | 2800 | 0.060 |
Why?
| | Treatment Failure | 1 | 2006 | 332 | 0.060 |
Why?
| | Feces | 2 | 2018 | 372 | 0.060 |
Why?
| | Biomarkers | 2 | 2016 | 3466 | 0.060 |
Why?
| | RNA | 1 | 2011 | 819 | 0.060 |
Why?
| | Cesarean Section | 1 | 2006 | 169 | 0.060 |
Why?
| | Protein Subunits | 1 | 2005 | 204 | 0.060 |
Why?
| | Animals | 6 | 2018 | 32102 | 0.060 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2005 | 274 | 0.060 |
Why?
| | Thyroid Neoplasms | 1 | 2007 | 262 | 0.060 |
Why?
| | Pre-Eclampsia | 1 | 2006 | 165 | 0.060 |
Why?
| | Monosaccharide Transport Proteins | 1 | 2003 | 45 | 0.060 |
Why?
| | Glucose Transporter Type 4 | 1 | 2003 | 36 | 0.060 |
Why?
| | Receptor, Insulin | 1 | 2003 | 93 | 0.060 |
Why?
| | Evidence-Based Medicine | 2 | 2012 | 684 | 0.060 |
Why?
| | Bifidobacterium | 1 | 2022 | 21 | 0.050 |
Why?
| | Glycerol | 1 | 2022 | 86 | 0.050 |
Why?
| | Anesthesia, Conduction | 1 | 2001 | 22 | 0.050 |
Why?
| | Physician-Nurse Relations | 1 | 2001 | 15 | 0.050 |
Why?
| | Organizational Objectives | 1 | 2001 | 71 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2003 | 804 | 0.050 |
Why?
| | Organizational Policy | 1 | 2001 | 69 | 0.050 |
Why?
| | Feeding Behavior | 2 | 2016 | 573 | 0.050 |
Why?
| | Vegetables | 1 | 2021 | 133 | 0.050 |
Why?
| | United Kingdom | 1 | 2001 | 227 | 0.050 |
Why?
| | Nurse's Role | 1 | 2001 | 106 | 0.040 |
Why?
| | Child | 2 | 2018 | 18488 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2416 | 0.040 |
Why?
| | Cell Membrane | 1 | 2003 | 683 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1000 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 289 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2005 | 2604 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 187 | 0.040 |
Why?
| | Germ-Free Life | 1 | 2018 | 30 | 0.040 |
Why?
| | National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2018 | 9 | 0.040 |
Why?
| | Polysomnography | 1 | 2019 | 135 | 0.040 |
Why?
| | Diet, Western | 1 | 2018 | 66 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2009 | 1872 | 0.040 |
Why?
| | Saliva | 1 | 2019 | 189 | 0.040 |
Why?
| | Sweden | 1 | 1997 | 65 | 0.040 |
Why?
| | England | 1 | 1997 | 63 | 0.040 |
Why?
| | Bile Acids and Salts | 1 | 2018 | 172 | 0.040 |
Why?
| | Fatty Acid Transport Proteins | 1 | 2017 | 18 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2019 | 273 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2018 | 220 | 0.040 |
Why?
| | Dysbiosis | 1 | 2018 | 146 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2020 | 1083 | 0.040 |
Why?
| | Factor V | 1 | 1996 | 22 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2017 | 149 | 0.030 |
Why?
| | Factor VIII | 1 | 1996 | 54 | 0.030 |
Why?
| | Lactobacillales | 1 | 2016 | 6 | 0.030 |
Why?
| | Gammaproteobacteria | 1 | 2016 | 14 | 0.030 |
Why?
| | Sirtuin 1 | 1 | 2016 | 29 | 0.030 |
Why?
| | Pyruvate Kinase | 1 | 2016 | 20 | 0.030 |
Why?
| | Stem Cells | 1 | 2020 | 546 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 2016 | 77 | 0.030 |
Why?
| | Receptors, Complement | 1 | 1996 | 111 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 4435 | 0.030 |
Why?
| | Factor Xa | 1 | 1995 | 32 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 1995 | 137 | 0.030 |
Why?
| | Arm | 1 | 2016 | 105 | 0.030 |
Why?
| | Stillbirth | 1 | 2015 | 57 | 0.030 |
Why?
| | Hemostasis | 1 | 1995 | 67 | 0.030 |
Why?
| | Pulmonary Alveoli | 1 | 1998 | 376 | 0.030 |
Why?
| | PPAR gamma | 1 | 2016 | 185 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2020 | 961 | 0.030 |
Why?
| | Adenylate Kinase | 1 | 2014 | 27 | 0.030 |
Why?
| | Leg | 1 | 2016 | 227 | 0.030 |
Why?
| | Bacteria | 1 | 2020 | 729 | 0.030 |
Why?
| | Electron Transport | 1 | 2014 | 112 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 795 | 0.030 |
Why?
| | Heart Valve Prosthesis | 1 | 1995 | 118 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2018 | 528 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 776 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 1995 | 724 | 0.030 |
Why?
| | Energy Intake | 1 | 2016 | 414 | 0.030 |
Why?
| | Antibodies | 1 | 1995 | 374 | 0.030 |
Why?
| | Oxygen | 1 | 1998 | 837 | 0.030 |
Why?
| | Blood Coagulation Disorders | 1 | 1995 | 196 | 0.030 |
Why?
| | Thyroiditis | 1 | 2012 | 3 | 0.030 |
Why?
| | Femur | 1 | 1994 | 194 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1440 | 0.030 |
Why?
| | Mass Screening | 1 | 2019 | 1024 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 1994 | 217 | 0.030 |
Why?
| | Sibling Relations | 1 | 1991 | 10 | 0.020 |
Why?
| | Liver | 1 | 2018 | 1690 | 0.020 |
Why?
| | Mother-Child Relations | 1 | 1991 | 110 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2006 | 12608 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 66 | 0.020 |
Why?
| | Intellectual Disability | 1 | 1991 | 129 | 0.020 |
Why?
| | Mastectomy, Segmental | 1 | 2009 | 76 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2018 | 4773 | 0.020 |
Why?
| | Mitochondria | 1 | 2014 | 750 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2009 | 218 | 0.020 |
Why?
| | Disabled Persons | 1 | 1991 | 135 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 174 | 0.020 |
Why?
| | Proteomics | 1 | 2014 | 859 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2009 | 141 | 0.020 |
Why?
| | Doxorubicin | 1 | 2009 | 290 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 53 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4113 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2007 | 137 | 0.020 |
Why?
| | Down Syndrome | 1 | 1991 | 336 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 514 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4665 | 0.020 |
Why?
| | Cattle | 1 | 2007 | 935 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1361 | 0.010 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 1998 | 10 | 0.010 |
Why?
| | Pulmonary Gas Exchange | 1 | 1998 | 113 | 0.010 |
Why?
| | Arteries | 1 | 1998 | 250 | 0.010 |
Why?
| | Gender Identity | 1 | 1991 | 103 | 0.010 |
Why?
| | Social Environment | 1 | 1991 | 286 | 0.010 |
Why?
| | Parenting | 1 | 1991 | 254 | 0.000 |
Why?
| | Child, Preschool | 1 | 1991 | 9133 | 0.000 |
Why?
|
|
Barbour's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|